Study of transcutaneous auricular neurostimulation as a treatment for alcohol use disorder
Active Project Grant Awarded Last action
- Award ID
- R41AA032157
- Recipient
-
Spark Biomedical Inc. UEI KUGZUDSCWQK5
- Awarding agency
-
National Institute on Alcohol Abuse and Alcoholism
National Institutes of Health, Department of Health and Human Services
- Obligated
- $305,545
Award facts
- Assistance listing
- 93.273 Alcohol Research Programs
- Completion date 57% complete
- Originally
- Place of performance
- Texas, USA
Award details come from USAspending.gov.
Description
- Abstract
- Alcohol use disorder (AUD) is a major health problem in the united states, often attributed to factors impacting the mesolimbic and cortico-striatal systems in the brain. Currently, there is a pressing need for the development of both therapeutic interventions and effective biomarkers for alcohol withdrawal syndrome (AWS) and alcohol- related psychiatric symptoms. One promising non-pharmacological approach is transcutaneous auricular neurostimulation (TAN), a non- invasive neurostimulation technique that stimulates neurotransmitter systems. TAN combines vagus nerve stimulation (VNS) and trigeminal nerve stimulation (TNS). Our study has shown that TAN is a safe and effective non-invasive treatment for reducing substance withdrawal symptoms, particularly those from opioids, suggesting its potential as a therapeutic tool for improving AWS. The aim is to lower a patient's desire for alcohol use and lessen the chance of relapse. Furthermore, another promising avenue is the integration of neuroimaging with clinical outcomes, aiming to establish an fmri-based objective biomarker for AUD. Incorporating TAN into this framework allows US to go beyond mere biomarker development, offering a unique and quantifiable therapeutic strategy. The proposed research endeavors to comprehensively investigate the efficacy of TAN as a treatment for AWS and the development of neuroimaging biomarkers in patients with AUD. This research initiative aims to provide a comprehensive clinical package, offering a valuable therapeutic tool. Ultimately, this work not only advances the application of TAN in clinical settings but also contributes significantly to the broader field of translational medical research.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $305,545 |
Quick answers
Who received award R41AA032157?
R41AA032157 was awarded to Spark Biomedical Inc. by National Institute on Alcohol Abuse and Alcoholism (National Institutes of Health) on September 1, 2025.
How much is award R41AA032157 worth?
$305,545 has been obligated on R41AA032157.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award